Open-angle glaucoma and cardiovascular mortality. The Blue Mountains Eye Study
Lee A.J., Wang J.J., Kiffley A., and Mitchell P. Open-angle glaucoma and cardiovascular mortality. The Blue Mountains Eye Study. Ophthalmology 113 (2006) 1069-1076
A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure. BEST, CIBIS-II, MERIT-HF, and COPERNICUS
Domanski M.J., Krause-Steinrauf H., Massie B.M., et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure. BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 9 (2003) 354-363
Perioperative beta-blocker therapy and mortality after major noncardiac surgery
Lindenauer P.K., Pekow P., Wang K., et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 353 (2005) 349-361
Statin and beta-blocker therapy and the initial presentation of coronary heart disease
Go A.S., Iribarren C., Chandra M., et al. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med 144 (2006) 229-238
The Ocular Hypertension Treatment Study. baseline factors that predict the onset of primary open-angle glaucoma
Gordon M.O., Beiser J.A., Brandt J.D., et al. The Ocular Hypertension Treatment Study. baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 714-720
Reduction of intraocular pressure and glaucoma progression. results from the Early Manifest Glaucoma Trial
Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression. results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120 (2002) 1268-1279
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Laaka H.M., Laaksonen D.E., Laaka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716